(2026). rs10010131A in WFS1 is Associated with Elevated Serum Urea in Type 2 Diabetes Patients Treated with SGLT2 Inhibitors. Therapeutics and Clinical Risk Management.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Rs10010131A in WFS1 Is Associated with Elevated Serum Urea in Type 2 Diabetes Patients Treated with SGLT2 Inhibitors."
Therapeutics and Clinical Risk Management 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Rs10010131A in WFS1 Is Associated with Elevated Serum Urea in Type 2 Diabetes Patients Treated with SGLT2 Inhibitors."
Therapeutics and Clinical Risk Management, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.